HOME >> MEDICINE >> NEWS
Yale prostate cancer study shows newer implant therapy has fewer side-effects, could lead to better treatment outcomes

New Haven, Conn. -- A Yale study of complication rates from two radiation implant therapies for prostate cancer shows that the newer therapy, Palladium-103, has fewer long-term side effects than Iodine-125, an older, more commonly prescribed therapy.

"While both implants were extraordinarily successful at preventing major long-term complications, Palladium-103 was superior to Iodine-125 in preventing moderate long-term complications by 13 percent," said Richard Peschel, M.D., professor of therapeutic radiology at Yale School of Medicine. "Our study is the first to compare prostate cancer implant therapies, and the results could lead to improved outcomes for patients."

In the seven-year study, Peschel and his team also found that the minimum dose for Palladium-103 could be increased without increasing side effects. This increased dose has the potential for improving cure rates, Peschel says.

Published in the Oct. 29 issue of Radiation Oncology Investigations: Clinical and Basic Research, the findings are significant for men facing a treatment decision for prostate cancer.

When diagnosed with prostate cancer, most men are presented with two treatment options: radical surgery and implant therapy, which involves placing 75 to 100 small radioactive seeds throughout the prostate using a one-time, minimally invasive procedure. Implant therapy is an increasingly popular choice because it is a cheaper, simpler out-patient procedure that involves far less recovery time, a lower complication rate and cure rates that are equivalent to radical surgery.

For 10 to 15 years, Iodine-125 was the most frequently prescribed implant treatment, but newer therapies have emerged, including Palladium-103. Prostate cancer implant programs using either Iodine-125 or Palladium-103 radioactive seeds have been extremely successful in treating early prostate cancer. About 30,000 prostate implants will be performed in the United States in the year 2000.

The resear
'"/>

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University
28-Oct-1999


Page: 1 2

Related medicine news :

1. Hormonal treatment improves survival in high-risk prostate cancer patients
2. Cultural and social factors influence prostate cancer treatment
3. Earlier use of prostate cancer vaccines urged by Hopkins scientists
4. Tumor-targeted immune cells cure prostate cancer in mice without causing systemic immune suppression
5. Men more likely to get screened for prostate cancer than colon cancer, U-M study finds
6. Mayo Clinic identifies key cellular process in prostate and other cancers
7. Obesity may affect accuracy of prostate screening
8. More precise radiation therapy lets prostate cancer patients avoid erectile dysfunction
9. Combining hormones with external, internal radiation helps high risk prostate cancer patients
10. Silent risk of osteoporosis in men with prostate cancer
11. NIH launches new study to compare prostate surgery and drugs

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology:
Cached News: